4.13
Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can r…
Drug displacement interactions arise when drugs compete for the same binding site, leading to displacement.
The extent of displacement depends on the concentration and binding site affinity of the displacer drug.
Displacement interactions can result in toxicity or insignificant clinical effects. For instance, phenylbutazone displaces warfarin from its binding sites, escalating free warfarin concentration and toxicity.
Furthermore, indirect interactions can also occur. For example, heparin triggers lipoprotein lipase, metabolizing triglycerides into free fatty acids. Concurrently, it reduces the protein binding of drugs like propranolol due to increased fatty acid levels.
Competition can occur between the body's constituents and drugs. Some drugs hinder bilirubin binding to albumin. The free bilirubin can cross the blood-brain barrier, leading to kernicterus in neonates.
Also, drugs can affect protein-binding interactions through allosteric changes in the protein molecule.
Aspirin, an allosteric effector, modifies albumin's capacity to bind NSAIDs by acetylating its lysine fraction.
View the full transcript and gain access to JoVE Core videos
Q1: What happens when two drugs compete for the same binding site?
When drugs compete for the same binding site, displacement interactions can occur where one drug displaces another from albumin or other blood proteins. The extent of displacement depends on the concentration and binding affinity of the displacer drug. This competition can result in increased free drug concentration of the displaced drug, potentially causing toxicity or insignificant clinical effects depending on the drug involved.
Q2: How does phenylbutazone affect warfarin in the body?
Phenylbutazone displaces warfarin from its binding sites on albumin, escalating the concentration of free warfarin in the bloodstream. This displacement interaction increases warfarin's availability and toxicity risk. The clinical consequence demonstrates how displacement interactions can significantly alter drug effects and create serious adverse outcomes when high-affinity drugs compete for limited binding sites.
Q3: What is an indirect drug interaction and how does heparin cause one?
Indirect interactions occur when one drug affects another drug's protein binding through secondary mechanisms rather than direct competition. Heparin triggers lipoprotein lipase, which metabolizes triglycerides into free fatty acids. These increased fatty acid levels reduce protein binding of drugs like propranolol by competing for albumin binding sites, demonstrating how metabolic changes can indirectly alter drug-protein interactions.
Q4: Why can drugs that inhibit bilirubin binding cause kernicterus in newborns?
Some drugs hinder bilirubin's ability to bind to albumin in blood plasma. When bilirubin remains unbound, it becomes lipophilic and can cross the blood-brain barrier, entering the central nervous system. In neonates, this free bilirubin accumulation causes kernicterus, a type of brain damage. This interaction illustrates competition between endogenous substances and drugs for protein binding sites.
Q5: How do allosteric changes in proteins affect drug binding?
Drugs can modify protein structure through allosteric changes, altering the protein's capacity to bind other drugs. Aspirin exemplifies this by acetylating albumin's lysine fraction, modifying albumin's ability to bind NSAIDs. These structural modifications change how NSAIDs interact with albumin, potentially altering their therapeutic effects. Allosteric interactions represent a distinct mechanism beyond direct binding site competition.
Q6: What determines the severity of a displacement interaction between drugs?
Displacement interaction severity depends on two key factors: the concentration of the displacer drug and its binding site affinity for the protein. Higher concentrations and stronger binding affinity increase the likelihood of displacing other drugs from albumin. These variables determine whether displacement causes clinically significant toxicity or negligible effects, making them critical for predicting drug interaction outcomes.
Q7: How can competition occur between the body's own substances and drugs?
Endogenous substances like bilirubin compete with drugs for limited protein binding sites on albumin and other blood proteins. When drugs occupy these sites, they reduce binding capacity for natural body constituents. This competition can have serious consequences, such as free bilirubin crossing the blood-brain barrier in neonates. Understanding these interactions is crucial for predicting clinical effects and avoiding adverse outcomes.